Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections - Full Text View

Purpose

Central venous catheters (CVCs) are used in patient care for such purposes as the administration of medication, fluids, blood products and for functions such as hemodialysis and plasmapheresis. However, the use of CVCs can cause complications such as life-threatening bloodstream infections (BSI).

BSIs are caused by organisms from the skin's surface tracking down the catheter's outer surface. The organisms grow on the catheter surface (catheter colonization) which is followed by seeding into the bloodstream. BSIs can be difficult to treat and the mortality rate is as high as 35% in Intensive Care patients with a catheter-related BSI. It is estimated that up to 70,000 patients in the US die each year from catheter-related BSI.

MBI 226 is a new drug that, when applied to the skin surrounding the catheter insertion site, may prevent organisms on the skin from migrating down the catheter and entering the bloodstream and therefore decrease the incidence of catheter-related BSI in patients with CVCs.

Condition	Intervention	Phase
Sepsis Bacteremia Fungemia	Drug: MBI 226	Phase III

MedlinePlus related topics:

Sepsis

Drug Information available for:

MBI-226 Omiganan pentahydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Active Control, Single Group Assignment, Safety/Efficacy Study

Official Title:	Phase III, Randomized, Open-Label Study to Assess the Safety and Efficacy of Topical Administration of MBI 226 1.0% Gel Versus Standard Medical Care in Patients Undergoing Non-Cuffed, Short-Term Arterial and/or Central Venous Catheterization

Further study details as provided by MIGENIX Inc.:

Primary Outcome Measures:

Reduction of catheter-related bloodstream infection

Secondary Outcome Measures:

Reduction of catheter colonization
Reduction of local catheter site infection

Estimated Enrollment:	1400
Study Start Date:	September 2000
Estimated Study Completion Date:	July 2003

Eligibility

Ages Eligible for Study:	16 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients undergoing non-cuffed arterial and/or central venous catheterization.
Patients able to give signed informed consent.
Concurrent antibiotic therapy is permitted.

Exclusion Criteria:

Treatment with an experimental topical, antibacterial, or antifungal drug within the previous 30 days.
Patients who are scheduled to receive catheters impregnated/bonded with an antimicrobial substance.
Patients requiring arterial or central venous catheterization for less than 48 hours or longer than 28 days.
Second or third degree burn patients.
Patients with a suspected or known bloodstream infection or local catheter insertion site infection.
Patients with a known allergy to adhesive tape or adhesive bandages.
Patients with a medical condition that the Investigator believes may interfere with the safety of the patient or the intent or conduct of the study.
Routine non-complicated post-operative CABG patients.
The disinfection procedure for catheter insertion did not include povidone-iodine.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00027248

Locations


United States, Illinois
	Omnicare Clinical Research Inc.
	Lake Bluff, Illinois, United States, 60044

Sponsors and Collaborators

MIGENIX Inc.

Investigators


Study Director:	Jim Pankovich	MIGENIX Inc.

More Information

Study ID Numbers:	226-98-002
First Received:	November 29, 2001
Last Updated:	September 12, 2005
ClinicalTrials.gov Identifier:	NCT00027248
Health Authority:	United States: Food and Drug Administration

Keywords provided by MIGENIX Inc.:

central venous catheter

bloodstream infection

CVC

catheter colonization

local catheter site infection

Study placed in the following topic categories:

Systemic Inflammatory Response Syndrome

Bacterial Infections

Mycoses

Sepsis

Fungemia

Bacteremia

Inflammation

Additional relevant MeSH terms:

Pathologic Processes

Infection

ClinicalTrials.gov processed this record on December 03, 2008

Sponsored by:	MIGENIX Inc.
Information provided by:	MIGENIX Inc.
ClinicalTrials.gov Identifier:	NCT00027248